Restricted stock

T2 Biosystems Reports Granting of Inducement Award

Retrieved on: 
금요일, 1월 29, 2021
Corporate finance, Stock market, Finance, Financial economics, Money, Employee stock ownership, Fundamental analysis, Restricted stock, Stock

The award was made on January 5, 2021 under T2 Biosystems Inducement Award Plan (the "Inducement Plan"), which was adopted March 1, 2018 (as amended to date) and provides for the granting of equity awards to new employees of T2 Biosystems.

Key Points: 
  • The award was made on January 5, 2021 under T2 Biosystems Inducement Award Plan (the "Inducement Plan"), which was adopted March 1, 2018 (as amended to date) and provides for the granting of equity awards to new employees of T2 Biosystems.
  • The inducement award consists of restricted stock units (RSUs) covering 460,992 shares of the Companys common stock.
  • The award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • The award was approved by the T2 Biosystems board of directors and was granted as an inducement material to the new employee entering into employment with T2 Biosystems in accordance with Nasdaq Marketplace Rule 5635(c)(4).

Moleculin Announces Reverse Stock Split

Retrieved on: 
금요일, 1월 29, 2021
Financial markets, Corporate finance, Financial economics, Finance, Stock market, Equity securities, Options, Fundamental analysis, Warrant, Restricted stock, Reverse stock split, Stock split

No fractional shares will be issued as a result of the reverse stock split.

Key Points: 
  • No fractional shares will be issued as a result of the reverse stock split.
  • As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 72.0 million shares to approximately 12.0 million shares, and the number of authorized shares of common stock will remain at 100 million shares.
  • As a result of the reverse stock split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards and warrants, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.
  • Forward-looking statements in this press release include, without limitation, the timing of the completion of the reverse stock split.

Qualtrics Announces Completion Of Exchange Offer

Retrieved on: 
목요일, 1월 28, 2021
Computer companies, Computing, Companies, Market research, Qualtrics, SAP, Exchange offer, Restricted stock

SALT LAKE CITY and SEATTLE, Jan. 28, 2021 /PRNewswire/ --Qualtrics announced today the successful completion of the exchange offer by Qualtrics and SAP to certain employees of Qualtrics, SAP and their subsidiaries to exchange all of their outstanding cash-settled fixed value rights and all of their outstanding cash-settled restricted stock units ("RSUs") of SAP for RSUs with respect to shares of Qualtrics Class A common stock.

Key Points: 
  • SALT LAKE CITY and SEATTLE, Jan. 28, 2021 /PRNewswire/ --Qualtrics announced today the successful completion of the exchange offer by Qualtrics and SAP to certain employees of Qualtrics, SAP and their subsidiaries to exchange all of their outstanding cash-settled fixed value rights and all of their outstanding cash-settled restricted stock units ("RSUs") of SAP for RSUs with respect to shares of Qualtrics Class A common stock.
  • The exchange offer expired, as scheduled, at 2:00 p.m. Eastern Time, on January 27, 2021.
  • Qualtrics also announced that the final exchange ratio in connection with the exchange offer is 4.2734 (number has been rounded).
  • The exchange agent for the exchange offer has advised Qualtrics and SAP that, as of the expiration of the exchange offer, a total of approximately 2,315 eligible employees had elected to tender their outstanding awards in the exchange offer and had not withdrawn their elections, representing approximately 91.71% of the value of the outstanding awards eligible to be tendered.

Pacific Biosciences Grants Equity Incentive Awards to New Employees

Retrieved on: 
화요일, 1월 12, 2021
Financial markets, Corporate finance, Stock market, Financial economics, Finance, Equity securities, Pacific Biosciences, DNA, Restricted stock, Stock, Read

MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options covering an aggregate of 750,000 shares of Pacific Biosciences common stock and restricted stock units (RSUs) covering 335,000 shares of Pacific Biosciences common stock to the Companys recently hired Chief Operating Officer, Mark Van Oene, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the Inducement Plan) effective on January 8, 2021.

Key Points: 
  • MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options covering an aggregate of 750,000 shares of Pacific Biosciences common stock and restricted stock units (RSUs) covering 335,000 shares of Pacific Biosciences common stock to the Companys recently hired Chief Operating Officer, Mark Van Oene, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the Inducement Plan) effective on January 8, 2021.
  • The Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and RSUs covering 50,000 shares of Pacific Biosciences common stock to a recently hired non-executive officer employee under the Inducement Plan, effective on January 7, 2021.
  • The option grants and the RSU awards are subject to the terms and conditions of the Inducement Plan and the award agreements entered into with the employees.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.

Synchronoss Technologies, Inc. Reports Inducement Grants to Employees Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
월요일, 1월 4, 2021
Corporate finance, Stock market, Finance, Financial economics, Money, Employee stock ownership, Fundamental analysis, Restricted stock, Executive compensation, Stock

Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors, and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • Each of these grants was an inducement award that was approved by the Compensation Committee of Synchronoss Board of Directors, and granted as an inducement equity award under the Company's 2017 New Hire Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Synchronoss granted the five newly hired employees an aggregate of 3,975 time-based restricted stock awards.
  • In addition, the employees received an aggregate of 1,325 time-based stock option awards.
  • Synchronoss secure, scalable and groundbreaking new technologies, trusted partnerships and talented people change the way TMT customers grow their business.

Iteris Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
월요일, 1월 4, 2021
Software, Internet, Hardware, Fleet management, Data management, Technology, Automotive, Other Transport, Engineering, Transport, Other Automotive, Manufacturing, Articles, Financial markets, Finance, Iteris, Inducement rule, NASDAQ, Restricted stock, Board of directors

(NASDAQ: ITI), the global leader in smart mobility infrastructure management, today announced that it has granted inducement awards to 17 new non-executive employees, who joined the company as a result of the recent TrafficCast International, Inc. acquisition.

Key Points: 
  • (NASDAQ: ITI), the global leader in smart mobility infrastructure management, today announced that it has granted inducement awards to 17 new non-executive employees, who joined the company as a result of the recent TrafficCast International, Inc. acquisition.
  • The awards were made on January 1, 2021 under Iteris 2020 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Iteris as an inducement to join the company.
  • The inducement awards to the 17 new non-executive employees consist of options to purchase an aggregate of 95,000 shares of Iteris common stock and 68,156 restricted stock units.
  • The awards were approved by Iteris board of directors, including a majority of Iteris independent directors, as required by Nasdaq Rule 5635(c)(4), and were granted as an inducement material to the new employees entering into employment with Iteris in accordance with Nasdaq Rule 5635(c)(4).

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
목요일, 12월 31, 2020
Financial markets, Finance, Corporate finance, Stock market, Financial economics, Options, Employee stock ownership, Fundamental analysis, Restricted stock, Stock, NASDAQ, Incentive stock option

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 4,525 shares of Sarepta's common stock, and in the aggregate, 1,720 restricted stock units (RSUs).
  • The options have an exercise price of $170.49 per share, which is equal to the closing price of Sarepta's common stock on December 31, 2020 (the Grant Date).
  • At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease.

Recro Grants Inducement Award to New Chief Executive Officer

Retrieved on: 
토요일, 12월 19, 2020
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, Vesting, NASDAQ, Stock, Option

The award consists of 217,822 restricted stock units and an option to purchase 194,175 shares of Recros common stock.

Key Points: 
  • The award consists of 217,822 restricted stock units and an option to purchase 194,175 shares of Recros common stock.
  • The award was granted on December 15, 2020 pursuant to the NASDAQ inducement grant exception as a component of Mr. Enloes compensation and was granted as an inducement material to his acceptance of employment with Recro in accordance with NASDAQ Listing Rule 5635(c)(4).
  • The options will vest in equal monthly installments over 48 months, beginning on January 15, 2021, subject to Mr. Enloes continued service with Recro through the applicable vesting date.
  • The options have an exercise price of $3.03 per share of Recro common stock and will expire on December 15, 2030.

Pacific Biosciences Grants Equity Incentive Award to New Employee

Retrieved on: 
금요일, 12월 18, 2020
Financial markets, Finance, Corporate finance, Financial economics, Stock market, Pacific Biosciences, Restricted stock, Stock, NASDAQ, Executive compensation

MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (RSU) covering 50,000 shares of Pacific Biosciences common stock to a recently hired non-executive officer employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the Effective Date).

Key Points: 
  • MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (Pacific Biosciences or the Company), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (RSU) covering 50,000 shares of Pacific Biosciences common stock to a recently hired non-executive officer employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the Effective Date).
  • The options have an exercise price of $20.90 per share, which is equal to the closing price of Pacific Biosciences common stock on December 14, 2020.
  • The option grant and the award of restricted stock units are subject to the terms and conditions of the 2020 Inducement Equity Incentive Plan and the award agreements entered into with the non-executive officer employee.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.

Noront Resources Issues Stock Based Compensation

Retrieved on: 
금요일, 12월 18, 2020
Ring of Fire, Restricted stock, Economy

TORONTO, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Noront Resources Ltd. (Noront or the Company) (TSX Venture: NOT) announced today that the Noront Board of Directors has granted 923,815 restricted stock units (RSUs) convertible into common shares of the Company six months from the date of grant, being June 18, 2021.

Key Points: 
  • TORONTO, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Noront Resources Ltd. (Noront or the Company) (TSX Venture: NOT) announced today that the Noront Board of Directors has granted 923,815 restricted stock units (RSUs) convertible into common shares of the Company six months from the date of grant, being June 18, 2021.
  • The RSUs were granted to various Directors, Officers and Management pursuant to Noronts share awards plan and will be used to compensate, incentivize, and retain key members of the Board, Officers and Management team.
  • The issuance of the RSUs is subject to all applicable regulatory and exchange approvals.
  • Noront Resources Ltd. is focused on development of its high-grade Eagles Nest nickel, copper, platinum and palladium deposit and the world class chromite deposits including Blackbird, Black Thor, and Big Daddy, all of which are located in the James Bay Lowlands of Ontario in an emerging metals camp known as the Ring of Fire.